2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - New Orleans Theatre B
Technology and Procedures, Omics Technologies, Computational Biology, Profiling, Biological Processes, Immune Mechanism, Metabolism, Diseases, Lymphoid Malignancies, Lymphomas, Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Research, Translational Research, Study Population, Human
PAPER

231 Malignant B-cell states orchestrate spatially organized immune ecosystems in B-cell lymphomas

Alisa Sadekova, MSc, Ksenia Fede2, Surendra Dasari, Associate Professor3, Wesley Au4, Moritz Binder, MD, MPH5, Kirill Kriukov, MD6, Mark Meerson, MSc7, Joseph Peter Novak, MS8, Zhi-Zhang Yang, MD9, Bri Negaard10, Ekaterina Postovalova, PhD11, Jose C Villasboas, MD12, Daniil Vibe13, Anastasiia Shvyrkova14, Emmanuel Contreras Guzman15, Nikita Kotlov16, Sargis Margaryan17, Alexander Nesmelov18, Alexander Sarachakov19, Arman Petrosyants20, Alexander Bagaev21, Yucai Wang, MD, PhD22, Anne J. Novak, PhD23, Carla Casulo, MD24, Thomas M. Habermann, MD25, Eric Hsi, M.D.26, Matthew E. Maurer, ScD27, James R. Cerhan, MD, PhD28, Nathan Fowler, MD29, Rebecca L. King, MD30, Mark Shlomchik, MD, PhD31, Harinder Singh32, Philippe Armand, MD33, Laura Pasqualucci, MD34, Richard Burack, MD, PhD35, Stephen Maxted Ansell, MD, PhD36, Patrizia Mondello, MD, PhD37
1 Bostongene, Waltham, Massachusetts, United States
2 Bostongene, Waltham, Massachusetts, United States
3 Mayo Clinic, Rochester, United States
4 Mayo Clinic, Rochester, United States
5 Mayo Clinic, Rochester, United States
6 Bostongene, Waltham, Massachusetts, United States
7 Bostongene, Waltham, Massachusetts, United States
8 Mayo Clinic, Rochester, United States
9 Mayo Clinic, Rochester, United States
10 Mayo Clinic, Rochester, United States
11 Bostongene, Waltham, Massachusetts, United States
12 Mayo Clinic, Rochester, United States
13 Bostongene, Waltham, Massachusetts, United States
14 Bostongene, Waltham, Massachusetts, United States
15 Mayo Clinic, Rochester, United States
16 Bostongene, Waltham, Massachusetts, United States
17 Bostongene, Waltham, Massachusetts, United States
18 Bostongene, Waltham, Massachusetts, United States
19 Bostongene, Waltham, Massachusetts, United States
20 Bostongene, Waltham, Massachusetts, United States
21 Bostongene, Waltham, Massachusetts, United States
22 Mayo Clinic, Rochester, United States
23 Mayo Clinic, Rochester, United States
24 Wilmot Cancer Institute, University of Rochester, Rochester, New York, United States
25 Mayo Clinic, Rochester, United States
26 Mayo Clinic, Rochester, United States
27 Mayo Clinic, Rochester, United States
28 Mayo Clinic, Rochester, United States
29 Bostongene, Waltham, Massachusetts, United States
30 Mayo Clinic, Rochester, United States
31 University of Pittsburgh School of Medicine, Pittsburgh, United States
32 University of Pittsburgh School of Medicine, Pittsburgh, United States
33 Mayo Clinic, Rochester, United States
34 Columbia University, New York, United States
35 Wilmot Cancer Institute, University of Rochester, Rochester, New York, United States
36 Mayo Clinic, Rochester, United States
37 Mayo Clinic, Rochester, United States

Background: Germinal center (GC)-derived lymphomas arise within specialized immune ecosystems, yet whether malignant B cells actively shape the tumor microenvironment (TME) or merely adapt to it remains unresolved.

Methods: We performed integrated multi-omics profiling of newly diagnosed follicular lymphoma (FL) and large B-cell lymphoma (LBCL), including bulk RNA-seq (FL1-3A n=86; FL3B n=11; LBCL n=304), WES (FL1-3A n=113; LBCL n=267), scRNA/BCR-seq (FL1-3A n=21; FL3B n=11; LBCL n=13), CyTOF (FL1-3A n=69; FL3B n=10), CODEX spatial proteomics (FL1-3A n=20; FL3B n=9; LBCL n=13), and functional validation in a genetically engineered mouse model.

Results: Transcriptional deconvolution identified two conserved TME states across FL and LBCL: immune-enriched ("hot") and immune-depleted ("cold"). These states were independent of histology or FL grade but strongly associated with tumor-intrinsic programs, including cell-of-origin (p<0.001), IRF4 signature (p<0.001) and GC differentiation state (p=0.02). Hot TMEs were enriched for post-GC/memory B-cell (MBC)-like programs, antigen presentation, IFNγ signaling, and immune infiltrates, whereas cold TMEs displayed proliferative dark zone (DZ)-like programs and immune-exclusion. CyTOF confirmed increased T cells (p=0.03), NK cells (p=0.002) and monocytes (p=0.01) in hot TMEs. Genomic profiling further supported these differentiation-associated immune states, with hot tumors enriched for mutations promoting post-GC differentiation (POU2AF1, IRF4, PRDM1), whereas cold tumors preferentially harbored alterations affecting DZ biology (MEF2B), antigen presentation (HLA-DRB1, HLA-A), and cell-cycle regulation (BCL2, TP53).

Single-cell trajectory analysis reconstructed a conserved differentiation continuum from a shared DZ-like progenitor to distinct terminal states across lymphoma subtypes. FL1–2 progressed toward transitioning GCB states, whereas FL3B bifurcated into MBC-like states resembling ABC-LBCL and LZ-like states aligned with FL, positioning FL3B as a transitional state during transformation. GCB-LBCL remained predominantly DZ-like, whereas ABC-LBCL occupied MBC-like terminal states. Progression along this continuum was accompanied by expansion of exhausted T cells, Tregs, macrophages and NK cells with depletion of naïve T cells. CellChat demonstrated inflammatory yet inhibitory signaling in MBC-like tumors (CXCL13-CXCR5, LGALS9), whereas DZ-like tumors preferentially engaged suppressive BTLA-TNFRSF14 signaling.

Spatial proteomics showed that differentiation programs were reflected in tissue architecture. FL1-3A retained organized GC-like B:T cell neighborhoods, whereas FL3B and LBCL displayed progressive spatial lymphocyte decoupling with increased myeloid and NK engagement. Graph neural network analysis identified 24 spatial communities spanning follicular, perifollicular and extrafollicular regions. Hot TMEs were enriched for extrafollicular T-cell/myeloid-rich communities, whereas cold TMEs were dominated by B-cell-rich communities. Among these, the intrafollicular DZ-enriched community predicted inferior survival across subtypes (HR 1.27, CI 95% 1.00-1.62), with a stronger effect in FL (HR 2.82, CI 95% 1.07-7.42).

To test if malignant differentiation directly instruct the TME, we generated a B-cell-restricted Irf4-deficient lymphoma mouse model (Cγ1cre;Irf4fl/fl;Bcl2) that enables in vivo manipulation of malignant cell fate and profiled tumors at 2 years by flow cytometry and scRNA/BCR-seq. Consistent with its role in plasma cell (PC) commitment, IRF4 loss markedly depleted PCs (p<0.001) with reciprocal expansion of MBCs (p=0.020), accompanied by transcriptional reprogramming toward post-GC differentiation (Sox5, Ebf1) while suppressing DZ-associated (Bcl6, Ezh2) and antigen presentation (H2-q7, H2-Ob) programs. Strikingly, this shift in malignant identity induced extensive immune remodeling that recapitulated the human immune-inflamed phenotype, including expansion of Tregs and myeloid cells (p<0.001). IRF4-deficient tumors displayed increased malignant-immune crosstalk characterized by reduced antigen presentation and co-stimulatory signaling with enhanced inhibitory signaling, whereas DZ-like lymphomas showed comparatively limited immune remodeling.

Conclusion: These findings establish malignant differentiation state as a causal determinant of immune architecture across GC-derived lymphomas and identify lineage-directed immune reprogramming as a potential therapeutic strategy

Patrizia Mondello, MD, PhD: No relevant conflicts of interest to declare.